UroGen Pharma announces updated 18-month DOR data from Phase 3 ENVISION trial

UroGen Pharma (URGN) announced an updated 18-month Duration of Response, DOR, of 80.6%, by Kaplan-Meier estimate, from the Phase 3 ENVISION trial of UGN-102 for intravesical solution, an investigational treatment for recurrent LG-IR-NMIBC. These data were featured in an Oral Presentation Session at the AUA 2025 Annual Meeting in Las Vegas, Nevada. “This new update from the pivotal ENVISION trial of UGN-102 demonstrated a compelling probability of remaining in complete response of 80.6% at 18 months in patients who achieved a complete response at three months,” said Sandip Prasad M.D., M.Phil., Director of Genitourinary Surgical Oncology, Vice Chair of Urology at Morristown Medical Center/Atlantic Health System, NJ, and Principal Investigator of the ENVISION trial. “Low-grade bladder cancer is a persistent cancer that frequently recurs and comes with its own risks. There is a significant unmet need in finding treatment options for patients with recurrent low-grade bladder cancer.”